The Chemistry in Health Innovation

16 December 2024 17:45 – 22:30
Location: Isala Building, Galileilaan 11, Niel, België
Category: Central division
On December 16th, KVCV will visit the Science Park of the University of Antwerp and ViTalent in Niel. There will be three keynote lectures in the field of "The Chemistry in Health Innovation." In addition, we will honor the laureates of the Chemistry Europe Fellows Award and the KVCV-SRC Incentive Awards, and some KVCV members will be honored as honorary members. There will also be guided tours through ViTalent.
 
About ViTalent
ViTalent is the first training center in Flanders offering practical, hands-on training for current and future employees in the life sciences sector, which includes pharma and biotech.

ViTalent is located in the Science Park of the University of Antwerp in Niel. Spanning an area of 1,500m², it features classrooms, laboratories, practical spaces with a cleanroom—everything needed to realistically simulate working conditions in pharmaceutical and biotech companies.
 
More information about ViTalent: vitalent.be
 
About Science Park University of Antwerp
The Science Park is a unique location for innovative, research-driven companies active in Health & Environment. This dynamic campus is in full development, located in a green oasis. As a developer, POM Antwerp is strongly committed to creating a motivating, inspiring work environment that offers companies, from start-up to multinational, every opportunity to grow successfully.
 
More information about Science Park University of Antwerp: wetenschapsparkuantwerpen.be
 
Language: English
 
Programme:
  • 17h45 Registration + Optional Sandwich Dinner
  • 18h15 Optional Guided Tours at ViTalent
  • 19h00 Welcome Address by the Chair of POM Antwerpen
  • 19h10 Keynote Lectures with the following speakers
  • 20h30 Tribute Ceremony
    • Chemistry Europe Fellows Award
      • Laureate Kristof Van Hecke (UGent) - From crystal to 3D structure: photodynamic “smart” crystals
    • KVCV-SRC Incentive Awards
      • Laureate Ibrahim Khalil (KU Leuven)
      • Laureate Enrico Cadoni (UGent)
    • Honorary Members KVCV
  • 21h15 Networking Reception
 
Registration fees (including guided tours & networking reception)
  • KVCV member: €13
  • KVCV student member: €5
  • Regular: €22
  • Student: €9

Fees optional items

  • Parking ticket: €3
  • Sandwich Dinner: €7
 
 
 
Abstracts
 
Immunopeptidomics, a MS based tool to decipher the immune system
 
Immunopeptidomics is the identification by affinity purification followed by MS analysis of immune peptides, short peptide fragments presented by MHC complexes on the surface of the cells. If these peptides are recognized as aberrant by the T cells, they can evoke an adaptive immune response. During this talk we will highlight some key applications of this cutting-edge technology (immunotherapy development, immunogenicity risk assessment of biotherapeutics, etc).
 
Developing tomorrow’s talent – turning innovation into production
 
In a fast-evolving eco system, both technical and legislative, and a tight labor market continuous training is not only a reality but also an absolute must. To address the topic of lifelong learning essenscia has developed a unique two-track policy that allows us to quickly adapt to newly emerging needs with the sectoral training facilities as well as create sustainable knowledge-transfer with schools, colleges and universities. Both tracks are symbiotic and provide a solid support for the production companies of the sector to implement new innovations knowing the talent they need, will be correctly trained.
 
Living drugs for Cancer: past, present and future
 
Cell therapy (so-called “living drugs”) has revolutionized cancer treatment and shows great promise beyond cancer as well. It involves modifying a patient's own immune cells to recognize and attack cancer cells. Advancements in this field have led to the development of CAR-T cell therapy and other immunotherapies, offering new hope for patients. Ongoing research and innovation hold the potential to further enhance the efficacy and widen the application of immune cell therapy in various diseases, paving the way for a brighter future in personalized medicine.
 
From crystal to 3D structure: photodynamic “smart” crystals
 
Single crystal X-ray diffraction (XRD) or crystallography is by far the most accurate way for uncovering the 3D structures of molecules down to the atomic level. This powerful technique allows us to explore the intricate structures of various compounds, including flexible and photodynamic molecular crystals. These crystals, made up of individual molecular units held together by weak intermolecular forces, have remarkable properties. For example, some can absorb light and convert it into mechanical motion, making them exciting candidates for advanced, smart materials like actuators and photonic devices.
Here, we showcase intriguing examples of photomechanical molecular single crystals that respond dramatically to UV light. These crystals exhibit controllable behavior, such as bending-shape recovery, and even violent splitting or jumping - phenomena known as "photosalient effects." These reactions are driven by precise single-crystal-to-single-crystal (SCSC) [2+2] cycloaddition reactions.
What’s even more exciting is that we have discovered new molecular combinations that exhibit these effects not only under UV light but also in visible sunlight. These reactions allow the rapid photosynthesis of unique polymers directly within the crystal structure, offering a sustainable pathway for material synthesis.
Our findings highlight the untapped potential of these light-responsive materials for future technologies, offering a glimpse into how molecular crystals could power innovative applications in smart materials, energy transformation, and beyond.
 
Speakers
 

Elise Pepermans (ImmuneSpec)

Elise Pepermans obtained her PhD in Biochemistry in the Pasteur Institut in Paris. During her post-doc in the Center for Proteomics (University of Antwerp/Flemish Institut for Technological Research) she developed an optimized sample preparation workflow for advanced immunopeptidomics. Since March 2023, she is one of the co-founders of ImmuneSpec, an advanced immunopeptidomics biotech company that offers high-sensitive immunopeptidomics as a service, thereby making this technique available to all biotech companies and researchers.

Kris Bosch (essenscia)

Kris Bosch is advisor education and labour market at essenscia, the Belgian sector federation of the chemical and life sciences industry. The organisation represents the specific interests of companies active in chemicals, plastics, pharma and biotech. Before joining essenscia, Kris held various HR and project management roles at sector company BASF, Brussels Airlines and Canadian NGO Right To Play. In his role at essenscia, Kris places a strong emphasis on the efforts that need to be made by education and industry to work more closely together, and on the regulatory framework that needs to be created to facilitate such a collaboration.

Viggo Van Tendeloo (Johnson & Johnson)
 
Viggo Van Tendeloo is part of the Johnson & Johnson Innovation team as an Early Innovation Partnering Director for the Benelux region. Within this role he focuses on the sourcing, screening and evaluation of opportunities and potential matches between internal and external research needs of high strategic value to Johnson & Johnson. In his previous role Viggo headed the EMEA Janssen Immunosciences team within the J&J World Without Disease Accelerator (WWDA) and the Lung Cancer Initiative (LCI) to drive new immunology drug targets towards NME stage. Viggo received a PhD in cell & gene therapy in 2000 at the University of Antwerp and was a full professor Cellular Immunotherapy at the Laboratory of Experimental Hematology of the University of Antwerp (2007-2023). He is co-founder of the first FAGG approved Center for Cell Therapy and Regenerative Medicine (CCRG) at the Antwerp University Hospital where he served as the scientific director until 2012 and later as Lab Director, Immunomonitoring & Translational Research. His team pioneered and successfully developed an autologous mRNA-engineered dendritic cell cancer vaccine for acute myeloid leukemia patients. He has authored over 150 publications (h-index of 54), several books and book chapters.
 
Kristof Van Hecke
 
Kristof Van Hecke is professor at Ghent University. His research group XStruct specializes in crystallization and structural analysis by X-ray diffraction. Among other methods, he uses these techniques in his research on the structure of new hybrid (nano)materials and flexible and photodynamic crystals as luminescent systems for optoelectronics and the conversion of light energy into mechanical motion. The applications of his research are endless, ranging from drug delivery to smart materials.
 

Register now 

 
 
This event is organized in collaboration with

 
With support of
 
 
 

Calendar

Search